[go: up one dir, main page]

HK1007683A1 - Treatment for inflammatory bowel disease - Google Patents

Treatment for inflammatory bowel disease Download PDF

Info

Publication number
HK1007683A1
HK1007683A1 HK98106928A HK98106928A HK1007683A1 HK 1007683 A1 HK1007683 A1 HK 1007683A1 HK 98106928 A HK98106928 A HK 98106928A HK 98106928 A HK98106928 A HK 98106928A HK 1007683 A1 HK1007683 A1 HK 1007683A1
Authority
HK
Hong Kong
Prior art keywords
antibody
vla
use according
inflammatory bowel
bowel disease
Prior art date
Application number
HK98106928A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1007683B (en
Inventor
R. Lobb Roy
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25268692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1007683(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of HK1007683B publication Critical patent/HK1007683B/en
Publication of HK1007683A1 publication Critical patent/HK1007683A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK98106928A 1992-02-12 1993-02-02 Treatment for inflammatory bowel disease HK1007683A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US835139 1986-03-03
US83513992A 1992-02-12 1992-02-12
PCT/US1993/000924 WO1993015764A1 (en) 1992-02-12 1993-02-02 Treatment for inflammatory bowel disease

Publications (2)

Publication Number Publication Date
HK1007683B HK1007683B (en) 1999-04-23
HK1007683A1 true HK1007683A1 (en) 1999-04-23

Family

ID=25268692

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98106928A HK1007683A1 (en) 1992-02-12 1993-02-02 Treatment for inflammatory bowel disease

Country Status (11)

Country Link
EP (1) EP0625912B1 (es)
JP (3) JPH07506566A (es)
AT (1) ATE151642T1 (es)
AU (1) AU674302B2 (es)
CA (1) CA2129637C (es)
DE (1) DE69309906T2 (es)
DK (1) DK0625912T3 (es)
ES (1) ES2103468T3 (es)
GR (1) GR3024041T3 (es)
HK (1) HK1007683A1 (es)
WO (1) WO1993015764A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
AU689454B2 (en) 1992-11-13 1998-04-02 Board Of Regents Of The University Of Washington, The Peripheralization of hematopoietic stem cells
AU727187B2 (en) * 1993-02-09 2000-12-07 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
CA2155303C (en) * 1993-02-09 2010-04-20 Linda C. Burkly Treatment for insulin dependent diabetes
ZA947006B (en) * 1993-09-15 1995-05-02 Univ Emory Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
HU220799B1 (hu) * 1994-01-25 2002-05-28 Elan Pharmaceuticals, Inc. Humanizált antitestek VLA-4 leukocita adhéziós molekula ellen
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CN1236815C (zh) 1998-09-14 2006-01-18 德克萨斯州立大学董事会 整联蛋白拮抗剂在制备治疗多发性骨髓瘤和骨髓瘤诱发的骨吸收的药物中的应用
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
ATE464299T1 (de) 2002-02-20 2010-04-15 Ajinomoto Kk Neues phenylalaninderivat
ES2531852T3 (es) 2002-02-25 2015-03-20 Biogen Idec Ma Inc. Administración de agentes para el tratamiento de la inflamación
AU2004303696B2 (en) 2003-12-22 2011-03-31 Ea Pharma Co., Ltd. Novel phenylalanine derivative
US20100150915A1 (en) 2007-02-20 2010-06-17 Stewart Edward J Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
JP4652356B2 (ja) 2007-02-26 2011-03-16 アルプス電気株式会社 ターンシグナルスイッチ装置
WO2009126920A2 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
EP3202789B1 (en) 2010-04-16 2020-05-06 Biogen MA Inc. Anti-vla-4 antibodies
UY34054A (es) 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN109884295B (zh) * 2017-12-25 2022-03-08 苏州和锐生物科技有限公司 假单胞菌多肽、抗体捕获器件及试剂盒
EP3800999A4 (en) 2018-06-04 2022-06-01 Biogen MA Inc. ANTI-VLA-4 ANTIBODY WITH REDUCED EFFECTIVE FUNCTION

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314863B1 (en) * 1987-11-02 1994-12-07 Baylor College Of Medicine Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
DK162890D0 (da) * 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid
HUT69725A (en) * 1991-10-01 1995-09-28 Gen Hospital Corp Process for producing compositions for preventing allograft rejection

Also Published As

Publication number Publication date
WO1993015764A1 (en) 1993-08-19
JP2007045843A (ja) 2007-02-22
CA2129637C (en) 1999-05-04
AU3605993A (en) 1993-09-03
GR3024041T3 (en) 1997-10-31
JPH07506566A (ja) 1995-07-20
JP4108572B2 (ja) 2008-06-25
ATE151642T1 (de) 1997-05-15
EP0625912B1 (en) 1997-04-16
CA2129637A1 (en) 1993-08-19
DK0625912T3 (da) 1997-10-27
JP2004002472A (ja) 2004-01-08
ES2103468T3 (es) 1997-09-16
EP0625912A1 (en) 1994-11-30
AU674302B2 (en) 1996-12-19
DE69309906D1 (de) 1997-05-22
DE69309906T2 (de) 1997-11-06

Similar Documents

Publication Publication Date Title
EP0625912B1 (en) Treatment for inflammatory bowel disease
HK1007683B (en) Treatment for inflammatory bowel disease
US6482409B1 (en) Treatment for inflammatory bowel disease with a vcam-1/1gG fusion protein
US5223426A (en) Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
EP2248529B1 (en) NKG2D antibodies for use in the treatment of autoimmune or inflammatory diseases
EP0289949A2 (en) Intercellular adhesion molecules, and their binding ligands
AU679506B2 (en) Intercellular adhesion molecules, and their binding ligands
EP0606518B1 (en) Intercellular adhesion molecules and their binding ligands
CA2134966C (en) Antibodies with specificity for multiple adhesion molecules
AU629189B2 (en) Intercellular adhesion molecules and their binding ligands
Pytowski et al. A monoclonal antibody to a human neutrophil-specific plasma membrane antigen. Effect of the antibody on the C3bi-mediated adherence by neutrophils and expression of the antigen during myelopoiesis.
EP0726942B1 (en) Monoclonal antibodies to foam cells and their pharmaceutical and diagnostic use
Kavanaugh Antiadhesion therapy in rheumatoid arthritis: A review of recent progress
WO1992008489A1 (en) Treatment for inflammatory bowel disease
CA2137813A1 (en) Methods and compositions for inhibiting endothelial cell and fibrinogen mediated inflammation
Stewart Production and characterisation of monoclonal antibodies to human glomerular mesangial cells
HK1021502A (en) Monoclonal antibodies reactive with defined regions of the t cell antigen receptor
IE83840B1 (en) Intercellular adhesion molecules, and their binding ligands
HK1003105B (en) Intercellular adhesion molecules, and their binding ligands

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100202